Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-3 Shelf registration
- 4.7 Form of Indenture, Between the Company and One or More Trustees to Be Named
- 4.9 Form of Common Stock Warrant Agreement and Warrant Certificate
- 4.10 Form of Preferred Stock Warrant Agreement and Warrant Certificate
- 4.11 Form of Debt Securities Warrant Agreement and Warrant Certificate
- 5.1 Opinion of Cooley LLP
- 23.1 Consent of Marcum LLP, Independent Registered Public Accounting Firm.
- 23.2 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
Associated filings
- 23 Sep 20 424B5 Prospectus supplement for primary offering
- 23 Sep 20 424B5 Prospectus supplement for primary offering
- 21 Sep 20 424B5 Prospectus supplement for primary offering
- 21 Sep 20 424B5 Prospectus supplement for primary offering
- 27 May 20 EFFECT Notice of effectiveness
-
14 May 20 S-3 Shelf registration
TARA similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of Protara Therapeutics, Inc. for the registration of common stock, preferred stock, debt securities, and warrants and to the incorporation by reference therein of our report dated March 19, 2020, with respect to the consolidated financial statements of Proteon Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
May 14, 2020